Vol 51 No 05

Here’s how the specialty fared vs other eligible clinicians.

"Although payers are supposed to adopt CPT instructions, we unfortunately do not have a system that contractually binds payers to follow CPT instructions verbatim," write Jonathan Rubenstein, MD, and Mark Painter.

"The need for maintaining the high quality of education within the increasing number of restrictions and regulations is making the job as program director complex and time-consuming," writes Gopal H. Badlani, MD.

What plays out in real-life courtrooms differs greatly from those on television.

Clinical guidelines currently do not recommend PSMA-PET imaging before radical prostatectomy.

The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.

Resist the temptation to overspend on unnecessary luxuries and upgrades.

The approval of pembrolizumab plus enfortumab vedotin in urothelial cancer was supported by results from the EV-103/KEYNOTE-869 trial.

Apalutamide is approved by the FDA for the treatment of patients with non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.

Prostate cancer, bladder cancer, renal cell carcinoma were among the multitude of tumor types assessed in the analysis supporting the approval.

No CxM-negative patients had findings of a recurrent tumor on a follow-up cystoscopy.

"If I had to boil down the advice, I would say that the most important thing that I did not know, that I've learned over time, is that you have to be prepared," says Stephanie Dukhovny, MD.

Black race was identified as an independent predictor of 30-day readmission even after investigators controlled for differences in patient demographics, clinical factors, and comorbidities.